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ABSTRAK
Latar belakang: inflamasi, stres oksidatif dan fibrosis memegang peran penting setelah terjadinya infark 
miokard akut (IMA). Biomarker inflamasi yang banyak dipelajari pada penyakit kardiovaskular adalah C-reactive 
protein. Ada bukti bahwa myeloperoksidase (MPO) dan galectin-3 (Gal-3) memegang peran penting pada sistem 
imun tubuh saat terjadi IMA. Penelitian ini bertujuan untuk melihat efek pemberian terapi tambahan N-acetylcystein 
(NAC) secara oral 600 mg 3 kali sehari selama 3 hari terhadap sistem imun pasien IMA. Metode: penelitian 
eksperimental acak, tersamar tunggal dengan metoda pre- dan post-test. Dilakukan di Rumah Sakit Dr. Moewardi 
Surakarta, dari bulan Mei hingga Agustus 2018. Tiga puluh dua pasien IMA dengan elevasi segmen ST (STEMI) 
yang mendapat terapi fibrinolitik masuk penelitian: 17 pasien mendapat terapi standar ditambah NAC 600 mg 
per oral setiap 8 jam selama 3 hari dan 15 pasien mendapat terapi standar sebagai kontrol. Kadar high sensitivity 
C-reaktif protein (HsCRP), MPO, dan Galectin-3 dari kedua kelompok diperiksa saat masuk dan setelah 72 jam 
perawatan. Hasil: kadar HsCRP, MPO, dan Gal-3 pada kelompok NAC dan kontrol pada saat admisi tidak berbeda 
bermakna, sedangkan kadar antar kelompok  pasca 72 jam pemberian NAC didapatkan perbedaan yang bermakna 
dengan nilai p untuk  kadar HsCRP, MPO, dan Gal-3 sebesar 0,0001, 0,001, dan 0,017. Pada kelompok NAC saat 
admisi dan pasca 72 jam, didapatkan perbedaan kadar HsCRP, MPO, dan Gal-3 yang bermakna dengan nilai 
p secara berurutan 0,0001, 0,0001 dan 0,0001; sedangkan pada kelompok kontrol tidak didapatkan perbedaan 
ini. Terdapat perbedaan kadar HsCRP, MPO, dan Gal-3 yang bermakna antara kelompok NAC dan kelompok 
kontrol (nilai p secara berurutan adalah 0,011, 0,022 dan 0,014). Kesimpulan: pemberian terapi tambahan NAC 
600 mg oral tiap 8 jam selama 72 jam dapat menurunkan kadar HsCRP, MPO, dan Gal-3 pada pasien IMA yang 
mendapatkan terapi fibrinolitik. Hasil penelitian ini akan memberikan pilihan terapi tambahan untuk pengelolaan 
pasien IMA yang lebih baik.
Kata kunci: infark miokard akut, N-acetylcystein, sistem imun.
ABSTRACT
Background: inflammation, oxidative stress, and fibrosis play important roles after an acute myocardial 
infarction (AMI) event. The most studied inflammatory biomarker in cardiovascular disease is C-reactive protein 
(CRP). It has been demonstrated that myeloperoxidase (MPO) and Galectin-3 (Gal-3) have some essential roles 
on immune system when an AMI event occurs. We aimed to determine the effect of oral N-acetylcysteine (NAC) 
supplementation at the dose of 600 mg 3 times daily for 3 consecutive days on the immune system of AMI patients. 
Methods: our randomized single-blinded experimental study using pre- and post-treatment evaluations was 
performed at Dr. Moewardi Hospital, Indonesia, from May to August 2018. Thirty-two patients with AMI and 
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ST segment elevation (STEMI) who received fibrinolytic therapy were included. There were 17 patients received 
standard therapy plus 600 mg oral NAC supplementation every 8 h for 3 days and 15 patients received standard 
therapy, which served as the control group. High-sensitivity C-reactive protein (HsCRP), MPO, and Gal-3 levels 
of both groups were evaluated at admission and after 72 h receiving treatment. Results: HsCRP, MPO, and Gal-3 
levels between NAC and control groups at admission were not significantly different; while intergroup differences 
after 72 h of NAC supplementation were significant (p values of HsCRP, MPO, and Gal-3 levels were 0.0001, 0.001, 
and 0.017, respectively). Furthermore, in the NAC group, HsCRP, MPO, and Gal-3 levels at 72 h after treatment 
were significantly different from the corresponding levels at admission (p values: 0.0001, 0.0001, and 0.0001, 
respectively); the control group did not show these differences. There were also significant intergroup differences 
between the NAC and control groups regarding HsCRP, MPO, and Gal-3 levels (p values: 0.011, 0.022, and 0.014, 
respectively). Conclusion: oral supplementation of 600 mg NAC every 8 h for 72 h can reduce HsCRP, MPO, 
and Gal-3 levels in AMI patients receiving fibrinolytic therapy. Results of our study will provide more options for 
supplementation therapy to improve management of IMA patients.
Keywords: acute myocardial infarction, N-acetylcysteine, immune system.
INTRODUCTION
Coronary heart disease (CHD) is the leading 
cause of death worldwide.1 In the United States, 
the incidence of acute myocardial infarction 
(AMI) with ST segment elevation (STEMI) 
decreases; while the incidence of AMI without ST 
segment elevation (NSTEMI) remains constant 
or slightly increases.2 In Indonesia, deaths from 
cardiovascular disease are increasing every year 
and cardiovascular disease has become the most 
common cause of death.3
Inflammation is an important factor in the 
development of atherosclerosis and subsequent 
cardiovascular events. Continuous inflammation 
increases the likelihood of erosion or rupture 
of atherosclerotic lesions. The most studied 
inflammatory biomarker in cardiovascular 
disease is C-reactive protein (CRP), an acute-
phase protein, which is produced mainly by 
hepatocytes under the influence of cytokines such 
as interleukin (IL)-6 and tumour necrosis factor-
alpha (TNF-α).4 Several studies have found that 
serum CRP levels can predict the risk of recurrent 
acute cardiovascular events in hospitals5 or 30-
day or long-term mortality in cases of STEMI.6 
The pathogenesis of AMI is influenced by 
systemic and local process on myocardial plaque 
and inflammation. Various types of leukocytes 
play an important role in local inflammatory 
processes and trigger plaque rupture, one of 
them is known as polymorphonuclear (PMN) 
neutrophils.7 PMN neutrophils play important 
roles in the innate and acquired immune systems. 
They accumulate in the inflammatory area and 
contribute to host endurance, regulation of the 
inflammatory process, and tissue injury. One 
important component of PMN neutrophils is 
myeloperoxidase (MPO).8
MPO is a member of a subfamily of 
peroxidases; it is mostly expressed in immune 
cells such as PMN cells, lymphocytes, monocytes, 
and other macrophages and cells. It is stored 
in the cytoplasmic membrane and binds to 
azurophilic granules. The mechanism of neutrophil 
degranulation is thought to be related to oxidative 
stress. MPO is involved in the production of 
reactive oxygen species (ROS) and other free 
radicals via a peroxidase or halogenation cycle. 
MPO is a strong oxidant, and if its levels are low 
and controlled, it is toxic to microorganisms and 
plays an important role in the immune system. 
However, if presents in excess and uncontrolled, 
MPO can cause host cell damage.9
Current evidence suggests that galectin 
plays an important role in acute and chronic 
inflammatory responses, as well as other diverse 
pathological processes.10 Galectin-3 (Gal-3) is 
expressed by almost all types of immune cells 
and inflammation, through constitutive and 
induction processes. It is a lectin that binds 
to β-galactoside and plays a major role in the 
development of cardiac fibrosis in conditions 
of excessive pressure (pressure overload), 
neuro-endocrine activation, and hypertension. 
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However, its role in remodelling after AMI has 
not received enough attention.11
In this study, we aimed to determine the 
effect of oral NAC supplementation at the dose 
of 600 mg 3 times daily for 3 consecutive days 
on the immune system of AMI patients who also 
were treated with fibrinolytics.
METHODS
Our study was a randomized, single-
blinded study involving pre- and post-treatment 
evaluations. The study was conducted at Dr. 
Moewardi General Hospital, Surakarta, from 
May to August 2018. This study has been 
approved by The Ethics Committee of Dr. 
Moewardi Hospital/Medical Faculty of Sebelas 
Maret University in Surakarta with a reference 
number 536/IV/HREC/2018 on May 16th, 2018.
Population and Samples
The study was conducted in 32 STEMI 
patients who received fibrinolytic therapy and 
underwent treatment at ICVCU Dr. Moewardi 
Surakarta, Central Java using consecutive 
sampling method. There were 17 patients in the 
N-acetylcysteine (NAC) group and 15 patients 
in the control group.
Study Variables
The independent variable in this study 
was NAC and the dependent variables were 
levels of high-sensitivity C-reactive protein 
(HsCRP), MPO, and Gal-3. The patients received 
effervescent NAC tablets (600 mg; Fuimucil®, 
Zambon Switzerland Ltd) thrice a day for 3 days.
The inclusion criteria for this study were 
STEMI patients with symptoms  who arrived at 
the hospital within 12 h and received fibrinolytic 
drugs, patients aged 18-75 years, and patients who 
had no absolute contraindications for fibrinolytic 
drugs. The exclusion criteria were patients with 
a history of acute coronary syndrome (ACS) 
or chronic heart failure, valvular heart disease, 
chronic renal failure, liver cirrhosis, chronic 
inflammatory disease or malignancy, an acute 
infection or sepsis, and stroke.
Study Instrumentation
Intravenous blood (volume: 4 mL) was 
collected before and at 72 h after NAC 
administration. Levels of HsCRP, MPO, and 
Gal-3 were determined using ELISA by PRODIA 
Laboratory.
Data Analysis
Data was presented in the form of mean 
and standard deviation. SPSS version 22.0 for 
windows was used for data analysis and the 
significant level was set at p < 0.05. To determine 
the mean difference before and after treatment in 
each groups, dependent sample t-test was used 
if data distribution was normal and wilcoxon 
was used if data distribution was not. Mean 
difference between the two groups and mean 
difference between changes (delta) before and 
after treatment in the treatment and control 
groups, the independent samples t-test was 
performed if the data distribution was normal 
and Mann-Whitney test was performed if the 
data distribution was not normal.
RESULTS
The basic characteristics of the patients are 
presented in Table 1. Intergroup differences were 
not significant between the NAC and control 
groups.
At admission, the levels of HsCRP, MPO, 
and Gal-3 in the NAC and control groups were 
not significantly different; however, intergroup 
differences in the levels were significant after 
72 h of NAC administration (p values: 0.0001, 
0.001, and 0.017, respectively) (Table 2).
In the NAC group, the levels of HsCRP, 
MPO, and Gal-3 at 72 h after NAC treatment were 
significantly different from the corresponding 
pre-treatment levels (P values:  0.0001, 0.0001, 
and 0.0001, respectively). Such differences 
were not found in the control group (Table 3). 
In addition, there were significant intergroup 
differences regarding the changes in HsCRP, 
MPO, and Gal-3 levels (P values:  0.011, 0.022, 
and 0.014, respectively) (Table 4).
DISCUSSION
This study was an experimental study 
with pre- and post-treatment evaluations that 
aimed to determine the effect of NAC 600 mg 
supplementary therapy administered orally 3 
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times a day for 3 days on HsCRP, MPO, and 
Gal-3 levels in STEMI patients who received 
fibrinolytic therapy.
Effect of N-Acetylcysteine on HsCRP
Inflammation associated with CHD and AMI 
triggers the formation of atheroma plaques in 
the coronary arteries. One parameter to assess 
the degree of inflammation in AMI is the 
measurement of CRP, an acute-phase protein 
produced mainly by hepatocytes under the 
Table 1. Basic characteristics
Variables






 - Male 16 (94.1) 12 (80.0)
 - Female 1 (5.9) 3 (20.0)
Age (years), mean 
(SD) 55.24 (10.19) 58.27 (8.07)
Risk Factors, n (%)
 - Hypertension 12 (70.6) 10 (66.7)
 - Smoking 13 (76.5) 9 (60.0)
 - Diabetes mellitus 5 (29.4) 1 (6.7)
Clinical Condition, mean (SD)
 - Onset (h) 4.82 (2.63) 4.80 (2.65)
 - Systolic blood 
pressure (mmHg) 136.71 (24.39) 132.20 (28.39)
 - Diastolic blood 
pressure (mmHg) 84.47 (17.57) 81.00 (18.68)
 - Heart rate (times/
min) 75.33 (19.09) 78.00 (11.93)
 - Killip I class n, 
(%) 13 (76.5) 10 (66.7)
 - Killip II-IV class 
n, (%) 4 (23.5) 5 (33.3)
 - Anterior STEMI 
n, (%) 11 (64.7) 8 (53.3)
 - Non-anterior 
STEMI n, (%) 6 (35.3) 7 (46.7)
Laboratory Parameters, mean (SD)
Haemoglobin (gr/dL) 13.75 (1.80) 13.59 (1.81)
eGFR (mL/min/1.73 
m) 64.40 (26.09) 72.13 (29.97)
LDL (mg/dL) 125.59 (33.41) 137.80 (83.90)
Triglycerides (mg/dL) 193.88 (149.46) 113.47 (46.69)
Therapy
Fibrinolytic therapy, n (%)
 - Success 2 (11.8) 4 (26.7)
 - Failure 15 (88.2) 11 (73.3)
ACE-I/ARB n, (%) 15(88.2) 14(93.3)
Beta blocker n, (%) 12(70.6) 14(93.3)
Table 2. Changes of biomarker levels in both groups
Parameters NAC group Control P value
HsCRP, median (range)
Admission 76.80  (10.80-270.60)
114.50  
(18.10-300.00) 0.089




Admission 162.91 (79.42) 168.34 (79.42) 0.825
72 h 112.76 (57.28) 180.40 (69.03) 0.001
Gal-3, mean (SD)
Admission 13.92 (4.49) 12.70 (3.94) 0.427
72 h 8.40 (2.55) 11.21 (3.70) 0.017
Data are presented as mean (standard deviation), except 
in the case of HsCRP, which is expressed as [median 
(min-max)]. HsCRP: high-sensitivity C-reactive protein; 
MPO: myeloperoxidase; Gal-3: galectin-3.
Table 3. Changes of biomarker levels in both groups
Parameters
NAC group
At Admission At 72 h
P 
value
HsCRP 76.80  (10.80-270.60)
14.90  
(3.60-266.80) 0.0001
MPO 162.92 (57.29) 112.76 (37.50) 0.0001
Gal-3 13.92 (4.49) 8.41 (2.55) 0.0001
Parameters
Control group
At Admission At 72 h
P 
value
HsCRP 114.50  (18.60-300.00)
151.50  
(42.50-285.20) 0.910
MPO 168.35 (79.42) 180.41 (69.04) 0.674
Gal-3 12.71 (3.95) 11.22 (3.71) 0.310
Data are presented as mean (standard deviation), except 
in the case of HsCRP, which is expressed as [median 
(min-max)]. HsCRP: high-sensitivity C-reactive protein; 
MPO: myeloperoxidase; Gal-3: galectin-3.
influence of proinflammatory cytokines such as 
interleukin (IL)-6 and tumour necrosis factor-
alpha (TNF -α).4 Several studies have shown that 
serum CRP levels can predict the risk of recurrent 
acute cardiovascular events in hospitals5 or 30-
day or long-term mortality in STEMI patients.6
In our study, HsCRP levels, as a marker 
of inflammation, were affected by oral NAC 
supplementation. Our finding is consistent with 
the theory that NAC has anti-inflammatory 
properties. Induction of the proinflammatory 
transcription factors activator protein-1 (AP-1) 
and nuclear factor-κB (NF-κB) is inhibited by 
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NAC. These transcription factors are induced in 
response to oxidative stress, thus supporting the 
argument that the anti-inflammatory properties 
of NAC are due to its mechanism of action as an 
antioxidant.12 Various studies have also shown 
that NAC supplementation can inhibit various 
inflammatory markers such as TNF-α, IL-6, 
IL-3, HsCRP, and C3, and soluble intercellular 
adhesion molecule (sICAM). It has been 
proven that NAC can also reduce ischemia of 
reperfusion, arrhythmia injury, and expansion 
of infarction. Fibrinolytic agents used in AMI 
patients can cause reperfusion injury with 
marked myocardial manifestations, arrhythmias, 
myocardial damage, and expansion of infarct 
size. NAC in combination with streptokinase 
significantly reduces oxidative stress and 
improves ventricular function in patients with 
myocardial infarction.13
Effect of N-Acetylcysteine on Myeloperoxidase
Oxidative stress and inflammation play an 
important role in the pathogenesis of CHD, 
which can cause AMI. In AMI with elevation of 
ST segment (AMI EST), neutrophil breakdown 
(degradation) occurs after neutrophil activation. 
Neutrophils contain granules that have mediators 
that play a role in delivering inflammatory 
signals. The granules consist of vesicles, 
azurophilic granules, and specific granules.7,14
Azurophilic granules consist of MPO, which 
is the largest protein in neutrophils. MPO is a 
strong oxidant, forming reactive oxidants and 
other free radicals through the peroxidase cycle 
or through a halogenization cycle depending 
on the availability of the substrate. In the 
peroxidase cycle, MPO activation occurs through 
the interaction of MPO with H2O2 to form 
H2O.7,9 NADPH oxidase is the main enzyme in 
neutrophils involved in the formation of ROS. 
The enzyme catalyses the reaction; therefore, the 
reaction is called respiratory burst or oxidative 
burst.14 Activation of MPO through halogenation 
involves halid (Cl-) and pseudohalid substrates 
such as thiocyanate/SCN-. This reaction causes 
the formation of hypochloric acid (HOCl-) 
and hypotonic acid (HOSCN-). The formation 
of reactive oxidants and other free radicals 
through the peroxidase cycle or through the 
halogenization cycle depends on the availability 
of the substrate.9
Based on the effect of MPO on the 
inflammatory response and oxidative stress, 
MPO inhibition strategies become therapeutic 
target. One agent that can inhibit MPO activity 
is NAC. This study shows MPO levels can be 
affected by oral NAC supplementation. NAC is 
a novel tripeptide that works as an antioxidant 
agent in various inflammatory pathways. It works 
optimally on hydroxyl radicals, hypochloric 
acid, and hydrogen peroxide. NAC inhibits the 
respiratory burst reaction in MPO activation, and 
can also reduce the formation of hypochlorous 
acid (HOCl) in MPO activation. It plays a role 
in stimulating antioxidant enzymes that reduce 
MPO activation.15
The results of our study are the same as those 
of the NACIAM trial conducted by Pasupathy 
et al.16 in 2017, which studied a high-dose 
intravenous NAC supplementation combined 
with a low-dose intravenous nitroglycerin 
therapy. In the NACIAM trial, the levels of 
MPO, malondialdehyde (MDA), and syndecan-1 
were determined. The study showed that MPO 
was significantly correlated to the amount of 
myocardium that can be saved by administering 
NAC and nitroglycerin therapy. Furthermore, 
MPO and other oxidative enzymes can be 
targeted in the pathogenesis of cardiovascular 
and inflammatory diseases. In our study, we 
analysed MPO levels after NAC supplementation 
in the treatment and control groups. There were 
Table 4. Comparison of changes in biomarker levels of both groups
Parameters NAC group Control group P value
HsCRP -25.10 [(-108)-(-1.80)] -5.50 [(-77)-253] 0.011
MPO -50.15 (46.62) 12.06 (108.65) 0.022
Gal-3 -5.51 (3.06) -1.49 (5.49) 0.014
Data are presented as mean (standard deviation), except in the case of HsCRP, which is expressed as [median (min-
max)]. HsCRP: high-sensitivity C-reactive protein; MPO: myeloperoxidase; Gal-3: galectin-3.
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increased MPO levels in the treatment group. 
MPO levels in NAC-treated patients tend to 
decrease.
Effect of N-Acetylcysteine on Galectin-3
Gal-3 is secreted by activated macrophages 
and modulates several physiological and 
pathological processes, including inflammation 
and fibrosis. It directly induces fibroblasts to 
proliferate and deposit type I collagen in the 
extracellular matrix.17,18 Remodelling after 
myocardial infarction is due to an acute loss of 
the myocardium, which causes structural and 
biomechanical changes in an effort to maintain 
cardiac function. Fibrosis is important in this 
process, including in the initial phase and after 
AMI.18
In a study by Van der Velde et al.19 in 
which 247 STEMI patients underwent primary 
percutaneous coronary intervention (PCI), Gal-3, 
as a fibrosis biomarker after AMI, could be used 
to predict left ventricular ejection fraction and 
infarct area after 4 months. Since Gal-3 has an 
important role in the pathophysiology of adverse 
cardiac remodelling and could be an independent 
predictor of heart failure after AMI, it can be 
hypothesized that a therapy that can inhibit Gal-
3 may affect the development of heart failure in 
patients with AMI.19
Transforming growth factor-β is an 
important mediator in the remodelling process.20 
Differentiation and activation of fibroblasts 
into myofibroblasts by inflammatory cytokines, 
such as TGF-β, starting with the entry of cells 
including macrophages, is the first step in the 
process of fibrogenesis. Gal-3 plays a role in 
this process when macrophages and TGF-β 
induce activation of myofibroblasts; however, 
recruitment of macrophages and expression of 
TGF-β do not depend on Gal-3.11
Our study findings indicate that oral NAC 
supplementation can affect Gal-3 levels. Results 
of our study are consistent with those of a study 
conducted by Talasaz et al.21 evaluating the effect 
of NAC on cardiac remodelling based on matrix 
metallopeptidase (MMP)-9 and MMP-2 levels 
in 98 AMI patients. In the group of patients who 
received additional oral NAC therapy, MMP-9 
and MMP-2 levels were significantly lower than 
the levels in the placebo group (P = 0.014 and 
P = 0.045, respectively). Talasaz et al.21 aimed 
to determine the effects of NAC on pro-fibrotic 
cytokines, TGF-β and TNF-α in AMI patients. 
They concluded that NAC supplementation can 
prevent an increase in TGF-β levels compared 
to that in patients who were not treated with 
NAC and that TGF-β is strongly associated with 
left ventricular ejection fraction, and therefore, 
its antagonism may be important in preventing 
remodelling.
The reduction in Gal-3 levels by NAC 
supplementation can be explained by an indirect 
inhibitory mechanism through NAC’s role as 
an antioxidant and anti-inflammatory agent. 
NAC, a direct antioxidant, is a ROS scavenger, 
but its main role as a therapeutic antioxidant 
agent is attributable to its role as a precursor of 
cysteine in the synthesis of glutathione. The role 
of NAC in inhibiting inflammation involves the 
inhibition of the induction of AP-1 and NF-κB 
proinflammatory transcription factors. These 
transcription factors are induced in response to 
oxidative stress.22
CONCLUSION
Oral NAC supplementation at the dose of 
600 mg 3 times daily for 3 days can reduce levels 
of HsCRP, MPO, and Gal-3 in AMI patients 
receiving fibrinolytic therapy. The findings of 
this study will provide a therapeutic option for 
the successful management of patients with AMI.
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